Tolerance Induction at the Early Maternal-Placental Interface Through Selective Cell Recruitment and Targeting by Immune Polypeptides

American Journal of Reproductive Immunology

Volumn 69, Issue 4, 2013, Pages 359-368

  Pérez Leirós, Claudia ^a   Ramhorst, Rosanna ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Chemokines; Maternal tolerance; Pregnancy; RANTES; Vasoactive intestinal peptide

Indexed keywords

CHEMOKINE RECEPTOR CCR1; CHEMOKINE RECEPTOR CCR3; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; RANTES; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE INTESTINAL POLYPEPTIDE;

CYTOKINE RELEASE; HOMEOSTASIS; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; MATERNAL PLACENTAL INTERFACE; MOLECULAR INTERACTION; MOTHER FETUS RELATIONSHIP; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; TH1 CELL; TH17 CELL;

CHEMOKINE CCL5; CHEMOKINES; FEMALE; FETUS; HUMANS; IMMUNE TOLERANCE; LYMPHOCYTE ACTIVATION; PLACENTA; PREGNANCY; T-LYMPHOCYTES, REGULATORY; TROPHOBLASTS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 84875051131     PISSN: 10467408     EISSN: 16000897     Source Type: Journal    
DOI: 10.1111/aji.12087     Document Type: Review

References (110)

1. Mor G, Cardenas I: The immune system in pregnancy: a unique complexity. Am J Reprod Immunol 2010; 63:425-433.
2. Redman CWG, Sargent IL: Immunology of pre-eclampsia. Am J Reprod Immunol 2010; 63:534-543.
3. Dekel N, Gnainsky Y, Granot I, Mor G: Inflammation and implantation. Am J Reprod Immunol 2010; 63:17-21.
4. Moser G, Gauster M, Orendi K, Glasner A, Theuerkauf R, Huppertz B: Endoglandular trophoblast, an alternative route of trophoblast invasion? Analysis with novel confrontation co-culture models. Hum Reprod 2010; 25:1127-1136.
5. Fitzgerald JS, Germeyer A, Huppertz B, Jeschke U, Knöfler M, Moser G, Scholz C, Sonderegger S, Toth B, Markert UR: Governing the invasive trophoblast: current aspects on intra- and extracellular regulation. Am J Reprod Immunol 2010; 63:492-505.
6. Burton GJ, Jauniaux E, Charnock-Jones DS: Human early placental development: potential roles of the endometrial glands. Placenta 2007; 28(Suppl A):S64-S69.
7. Daher S, de Arruda Geraldes Denardi K, Blotta MH, Mamoni RL, Reck AP, Camano L, Mattar R: Cytokines in recurrent pregnancy loss. J Reprod Immunol 2004; 62:151-157.
8. Clark DA, Yu G, Arck PC, Levy GA, Gorczynski RM: MD-1 is a critical part of the mechanism causing Th1-cytokine-triggered murine fetal loss syndrome. Am J Reprod Immunol 2003; 49:297-307.
9. Kwak-Kim J, Yang KM, Gilman-Sachs A: Recurrent pregnancy loss: a disease of inflammation and coagulation. J Obstet Gynaecol Res 2009; 35:609-622.
10. Girardi G, Yarilin D, Thurman JM, Holers VM, Salmon JE: Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006; 203:2165-2175.
11. Gomez-Lopez N, Guilbert LJ, Olson DM: Invasion of the leukocytes into the fetal-maternal interface during pregnancy. J Leukoc Biol 2010; 88:625-633.
12. Ashkar AA, Di Santo JP, Croy BA: Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy. J Exp Med 2000; 192:259-270.
13. van den Heuvel MJ, Xie X, Tayade C, Peralta C, Fang Y, Leonard S, Paffaro Jr VA, Sheikhi AK, Murrant C, Croy BA: A review of trafficking and activation of uterine natural killer cells. Am J Reprod Immunol 2005; 54:322-331.
14. Harris LK: IFPA Gabor Than Award lecture: transformation of the spiral arteries in human pregnancy: key events in the remodelling timeline. Placenta 2011; 32(Suppl 2):S154-S158.
15. Moffett-King A: Natural killer cells and pregnancy. Nat Rev Immunol 2002; 2:656-663.
16. Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, Prus D, Cohen-Daniel L, Arnon TI, Manaster I, Gazit R, Yutkin V, Benharroch D, Porgador A, Keshet E, Yagel S, Mandelboim O: Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006; 12:1065-1074.
17. Mosser DM, Edwards JP: Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8:958-969.
18. Strazewski Chavez SL, Abrahams VM, Mor G: The role of apoptosis in the regulation of trophoblast survival and differentiation during pregnancy. Endocr Rev 2005; 26:877-897.
19. Fest S, Aldo PB, Abrahams VM, Visintin I, Alvero A, Chen R, Chavez SL, Romero R, Mor G: Trophoblast-macrophage interactions: a regulatory network for the protection of pregnancy. Am J Reprod Immunol 2007; 57:55-66.
20. Abrahams VM, Kim YM, Straszewski SL, Romero R, Mor G: Macrophages and apoptotic cell clearance during pregnancy. Am J Reprod Immunol 2004; 51:275-282.
21. Nagamatsu T, Schust DJ: The contribution of macrophages to normal and pathological pregnancies. Am J Reprod Immunol 2010; 63:460-471.
22. Aluvihare VR, Kallikourdis M, Betz AG: Regulatory T cells mediate maternal tolerance to the fetus. Nat Immunol 2004; 5:266-271.
23. Terness P, Kallikourdis M, Betz AG, Rabinovich GA, Saito S, Clark DA: Tolerance signaling molecules and pregnancy: IDO, galectins, and the renaissance of regulatory T cells. Am J Reprod Immunol 2007; 58:238-254.
24. Leber A, Teles A, Zenclussen AC: Regulatory T cells and their role in pregnancy. Am J Reprod Immunol 2010; 63:445-459.
25. Zenclussen AC, Gerlof K, Zenclussen ML, Sollwedel A, Bertoja AZ, Ritter T, Kotsch K, Leber J, Volk HD: Abnormal T-cell reactivity against paternal antigens in spontaneous abortion: adoptive transfer of pregnancy-induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine abortion model. Am J Pathol 2005; 166:811-822.
26. Ramhorst R, Fraccaroli L, Aldo P, Alvero AB, Cardenas I, Perez Leirós C, Mor G: Modulation and recruitment of inducible regulatory T cells by first trimester trophoblast cells. Am J Reprod Immunol 2012; 67:17-27.
27. Saito S, Nakashima A, Shima T, Ito M: Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol 2010; 63:601-610.
28. Schumacher A, Wafula PO, Teles A, El-Mousleh T, Linzke N, Zenclussen ML, Langwisch S, Heinze K, Wollenberg I, Casalis PA, Volk HD, Fest S, Zenclussen AC: Blockage of heme oxygenase-1 abrogates the protective effect of regulatory T cells on murine pregnancy and promotes the maturation of dendritic cells. PLoS ONE 2012; 7:e42301.
29. Munoz-Suano A, Hamilton AB, Betz AG: Gimme shelter: the immune system during pregnancy. Immunol Rev 2011; 241:20-38.
30. Warning JC, McCracken SA, Morris JM: A balancing act: mechanisms by which the fetus avoids rejection by the maternal immune system. Reproduction 2011; 141:715-724.
31. Rossi D, Zlotnik A: The biology of chemokines and their receptors. Annu Rev Immunol 2000; 18:217-242.
32. Bromley SK, Mempel TR, Luster AD: Orchestrating the orchestrators: chemokines in control of T cell traffic. Nat Immunol 2008; 9:970-980.
33. Fraccaroli L, Alfieri J, Pérez Leiros C, Ramhorst R: Immunomodulatory effects of chemokines during the early implantation window. Front Biosc 2009; 1:288-298.
34. Lutther AJ, Cyster AC: Chemokines as regulators of T cell differentiation. Nat Med 2001; 2:102-107.
35. Moser B, Loetscher P: Lymphocyte traffic control by chemokines. Nat Med 2001; 2:123-128.
36. Sohy D, Yano H, de Nadai P, Urizar E, Guillabert A, Javitch JA, Parmentier M, Springael JY: Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists. J Biol Chem 2009; 284:31270-31279.
37. Raman D, Sobolik-Delmaire T, Richmond A: Chemokines in health and disease. Exp Cell Res 2011; 317:575-589.
38. Neel NF, Barzik M, Raman D, Sobolik-Delmaire T, Sai J, Ham AJ, Mernaugh RL, Gertler FB, Richmond A: VASP is a CXCR2-interacting protein that regulates CXCR2-mediated polarization and chemotaxis. J Cell Sci 2009; 122:1882-1894.
39. Raman D, Neel NF, Sai J, Mernaugh RL, Ham AJ, Richmond AJ: Characterization of chemokine receptor CXCR2 interacting proteins using a proteomics approach to define the CXCR2 "chemosynapse". Methods Enzymol 2009; 460:315-330.
40. Raman D, Sai J, Neel NF, Chew CS, Richmond A: LIM and SH3 protein-1 modulates CXCR2- mediated cell migration. PLoS ONE 2010; 5:e10050.
41. Kallikourdis M, Andersen KG, Welch KA, Betz AG: Alloantigen-enhanced accumulation of CCR5+ effector regulatory T cells in the gravid uterus. PNAS 2007; 104:594-599.
42. Mold JE, Michaëlsson J, Burt TD, Muench MO, Beckerman PK, Busch MP, Lee T, Nixon DF, McCune JM: Maternal alloantigens promote the development of tolerogenic fetal regulatory t cells in utero. Science 2008; 322:1562-1565.
43. Mjösberg J, Svensson J, Johansson E, Hellström L, Casas R, Jenmalm MC, Boij R, Matthiesen L, Jönsson JI, Berg G, Ernerudh J: Systemic reduction of functionally suppressive CD4dimCD25highFoxp3+ Tregs in human second trimester pregnancy is induced by progesterone and 17beta-estradiol. J Immunol 2009; 183:759-769.
44. Mjösberg J, Berg G, Jenmalm MC, Ernerudh J: FOXP3+ regulatory T cells and T helper 1, T helper 2, and T helper 17 cells in human early pregnancy decidua. Biol Reprod 2010; 82:698-705.
45. Tilburgs T, Roelen DL, van der Mast BJ, de Groot-Swings GM, Kleijburg C, Scherjon SA, Claas FH: Evidence for a selective migration of fetus-specific CD4+CD25bright regulatory T cells from the peripheral blood to the decidua in human pregnancy. J Immunol 2008; 180:5737-5745.
46. Tilburgs T, Schonkeren D, Eikmans M, Nagtzaam NM, Datema G, Swings GM, Prins F, van Lith JM, van der Mast BJ, Roelen DL, Scherjon SA, Claas FH: Human decidual tissue contains differentiated CD8+ effector-memory T cells with unique properties. J Immunol 2010; 185:4470-4477.
47. Graham CH, Hawley TS, Hawley RG, MacDougall JR, Kerbel RS, Khoo N, Lala PK: Establishment and characterization of first trimester human trophoblast cells with extended lifespan. Exp Cell Res 1993; 206:204-211.
48. Straszewski-Chavez SL, Abrahams VM, Alvero AB, Aldo PB, Ma Y, Guller S, Romero R, Mor G: The isolation and characterization of a novel telomerase immortalized first trimester trophoblast cell line, Swan 71. Placenta 2009; 30:939-948.
49. Nancy P, Tagliani E, Tay CS, Asp P, Levy DE, Erlebacher A: Chemokine gene silencing in decidual stromal cells limits T cell access to the maternal-fetal interface. Science 2012; 336:1317-1321.
50. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1αand MIP-1β as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995; 270:1811-1815.
51. Hornung D, Klingel K, Dohrn K, Kandolf R, Wallwiener D, Tayler RN: Regulated on activation, normal T-cell expressed and -secreted mRNA expression in normal endometrium and endometriotic implants: assessment of autocrine/paracrine regulation by in situ hybridization. Am J Pathol 2001; 158:1949-1954.
52. Faunce D, Stein-Streilein J: NKT Cell-derived RANTES recruits APCs and CD8+ T cells to the spleen during the generation of regulatory T cells in tolerance. J Immunol 2002; 169:31-38.
53. Nakamura T, Sonoda K, Faunce D, Gumperz J, Yamamura T, Miyake S, Stein-Streilein T: CD4+ NKT cells, but not conventional CD4+ T cells are required to generate efferent CD8+ T regulatory cells following antigen inoculation in an immune-privileged site. J Immunol 2003; 171:1266-1271.
54. Rabinovich GA, Ramhorst RE, Rubinstein N, Corigliano A, Daroqui MC, Kier-Joffé EB, Fainboim L: Induction of allogenic T-cell hyporesponsiveness by galectin-1-mediated apoptotic and non-apoptotic mechanisms. Cell Death Differ 2002; 9:661-670.
55. Ramhorst R, Patel R, Corigliano A, Etchepareborda JJ, Fainboim L, Schust D: Induction of maternal tolerance to fetal alloantigens by RANTES production. Am J Reprod Immunol 2006; 56:302-311.
56. Paria B, Reese J, Das S, Dey S: Deciphering the cross talk of implantation: advances and challenges. Science 2002; 296:2185-2188.
57. Fraccaroli L, Alfieri J, Larocca L, Calafat M, Mor G, Pérez Leiros C, Ramhorst R: A potential tolerogenic immune mechanism in a trophoblast cell line through the activation of chemokine-induced T cell death and regulatory T cell modulation. Hum Reprod 2009; 24:166-175.
58. Ramhorst R, Gutiérrez G, Corigliano A, Junovich G, Fainboim L: Implication of RANTES in the modulation of alloimmune response by progesterone during pregnancy. Am J Reprod Immunol 2007; 57:147-152.
59. Kim MJ, Romero R, Kim CJ, Tarca AL, Chhauy S, LaJeunesse C, Lee DC, Draghici S, Gotsch F, Kusanovic JP, Hassan SS, Kim JS: Villitis of unknown etiology is associated with a distinct pattern of chemokine up-regulation in the feto-maternal and placental compartments: implications for conjoint maternal allograft rejection and maternal anti-fetal graft-versus-host disease. J Immunol 2009; 182:3919-3927.
60. Fraccaroli L, Grasso E, Hauk V, Cortelezzi M, Calo G, Pérez Leirós C, Ramhorst R: Defects in the vasoactive intestinal peptide (VIP)/VPAC system during early stages of the placental-maternal leucocyte interaction impair the maternal tolerogenic response. Clin Exp Immunol 2012; 170:310-320.
61. Said SI: The discovery of VIP: initially looked for in the lung, isolated from intestine, and identified as a neuropeptide. Peptides 2007; 28:1620-1621.
62. Couvineau A, Laburthe M: VPAC receptors: structure, molecular pharmacology and interaction with accessory proteins. Br J Pharmacol 2012; 166:42-50.
63. Onoue S, Misaka S, Yamada S: Structure-activity relationship of vasoactive intestinal peptide (VIP): potent agonists and potential clinical applications. Naunyn-Schmiedeberg's Arch Pharmacol 2008; 377:579-590.
64. Harmar AJ, Fahrenkrug J, Gozes I, Laburthe M, May V, Pisegna JR, Vaudry D, Vaudry H, Waschek JA, Said SI: Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol 2012; 166:4-17.
65. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D: Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. J Immunol 1999; 162:4685-4696.
66. Gressens P, Marret S, Hill JM, Brenneman DE, Gozes I, Fridkin M, Evrard P: Vasoactive intestinal peptide prevents excitotoxic cell death in the murine developing brain. J Clin Invest 1997; 100:390-397.
67. Månsson B, Nilsson BO, Ekström J: Effects of repeated infusions of substance P and vasoactive intestinal peptide on the weights of salivary glands subjected to atrophying influences in rats. Br J Pharmacol 1990; 101:853-858.
68. Ekström J, Mansson B, Tobin G: Vasoactive intestinal peptide evokes secretion of fluid and protein from rat salivary glands and the development of supersensitivity. Acta Physiol Scand 1983; 119:169-175.
69. Jovanovic S, Grbovic L, Jovanovic A: Pregnancy does not alter the response of uterine arteries to vasoactive intestinal polypeptide. Mol Hum Reprod 2000; 6:361-368.
70. Roca V, Larocca L, Calafat M, Aisemberg J, Meiss R, Franchi A, Perez Leiros C: Reduced nitric oxide synthase and cyclo-oxygenase activity in the uterus of non-obese diabetic mice. Reproduction 2006; 32:931-938.
71. Lara-Marquez M, O'Dorisio M, O'Dorisio T, Shah M, Karacay B: Selective gene expression and activation-dependent regulation of vasoactive intestinal peptide receptor type 1 and type 2 in human T cells. J Immunol 2006; 166:2522-2530.
72. Martinez C, Delgado M, Abad C, Gomariz RP, Ganea D, Leceta J: Regulation of VIP production and secretion by murine lymphocytes. J Neuroimmunol 1999; 93:126-138.
73. Li JM, Southerland L, Hossain MS, Giver CR, Wang Y, Darlak K, Harris W, Waschek J, Waller EK: Absence of vasoactive intestinal peptide expression in hematopoietic cells enhances Th1 polarization and antiviral immunity in mice. J Immunol 2011; 187:1057-1065.
74. Lodde BM, Mineshiba F, Wang J, Cotrim P, Afione S, Tak PP, Baum BJ: Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjogren's syndrome. Ann Rheum Dis 2006; 65:195-200.
75. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP: Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001; 7:563-568.
76. Gonzalez-Rey E, Delgado M: Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med 2007; 13:241-251.
77. Yadav M, Goetzl EJ: Vasoactive intestinal peptide-mediated Th17 differentiation: an expanding spectrum of vasoactive intestinal peptide effects in immunity and autoimmunity. Ann N Y Acad Sci 2008; 1144:83-89.
78. Jimeno R, Gomariz RP, Gutiérrez-Cañas I, Martínez C, Juarranz Y, Leceta J: New insights into the role of VIP on the ratio of T-cell subsets during the development of autoimmune diabetes. Immunol Cell Biol 2010; 88:734-745.
79. Rosignoli F, Torroba M, Juarranz Y, Gomez IA, Martinez C, Gomariz RP, Pérez Leirós C, Leceta J: VIP and tolerance induction in autoimmunity. Ann N Y Acad Sci 2006; 6:1-6.
80. Chorny A, Gonzalez-Rey E, Fernandez Martin A, Ganea D, Delgado M: Vasointestinal peptide induces regulatory dendritic cells that prevent acute graft-host disease while maintaining the graft-versus tumor response. Blood 2006; 107:3787-3794.
81. Toscano MG, Delgado M, Kong W, Martin F, Skarica M, Ganea D: Dendritic cells transduced with lentiviral vectors expressing VIP differentiate into VIP-secreting tolerogenic-like DCs. Mol Ther 2010; 18:1035-1045.
82. Juarranz MG, Santiago B, Torroba M, Gutierrez-Cañas I, Palao G, Galindo M, Abad C, Martinez C, Leceta J, Pablos JL, Gomariz RP: Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells. Rheumatology 2004; 43:416-422.
83. Carrión M, Juarranz Y, Pérez-García S, Jimeno R, Pablos JL, Gomariz RP, Gutiérrez-Cañas I: RNA sensors in human osteoarthritis and rheumatoid arthritis synovial fibroblasts: immune regulation by vasoactive intestinal peptide. Arthritis Rheum 2011; 63:1626-1636.
84. Jimeno R, Leceta J, Martínez C, Gutiérrez-Cañas I, Pérez-García S, Carrión M, Gomariz RP, Juarranz Y: Effect of VIP on the balance between cytokines and master regulators of activated helper T cells. Immunol Cell Biol 2012; 90:178-186.
85. Pozo D, Anderson P, Gonzalez-Rey E: Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide. J Immunol 2009; 183:4346-4359.
86. Yadav M, Rosenbaum J, Goetzl EJ: Cutting edge: vasoactive intestinal peptide (VIP) induces differentiation of Th17 cells with a distinctive cytokine profile. J Immunol 2008; 180:2772-2776.
87. Said SI, Hamidi SA, Gonzalez Bosc L: Asthma and pulmonary arterial hypertension: do they share a key mechanism of pathogenesis? Eur Respir J 2010; 35:730-734.
88. Leceta J, Martínez C, Delgado M, Garrido E, Gomariz RP: Expression of vasoactive intestinal peptide in lymphocytes: a possible endogenous role in the regulation of the immune system. Adv Neuroimmunol 1996; 6:29-36.
89. Voice JK, Grinninger C, Kong Y, Bangale Y, Paul S, Goetzl EJ: Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol 2003; 170:308-314.
90. Hill JM, McCune SK, Alvero RJ, Glazner GW, Henins KA, Stanziale SF, Keimowitz JR, Brenneman DE: Maternal vasoactive intestinal peptide and the regulation of embryonic growth in the rodent. J Clin Invest 1996; 97:202-208.
91. Spong CY, Lee SJ, McCune SK, Gibney G, Abebe DT, Brenneman DE, Hill JM: Regulation of postimplantation mouse embryonic growth by maternal vasoactive intestinal peptide. Ann N Y Acad Sci 1999; 897:101-108.
92. Spong C, Lee S, Mcune S, Gibney G, Abebe D, Alvero R, Brenneman E, Hill G: Maternal regulation of embryonic growth: the role of vasoactive intestinal peptide. Endocrinology 1999; 140:917-924.
93. Hill JM, Hauser JM, Sheppard LM, Abebe D, Spivak-Pohis I, Kushnir M, Deitch I, Gozes I: Blockage of VIP during mouse embryogenesis modifies adult behavior and results in permanent changes in brain chemistry. J Mol Neurosci 2007; 31:183-200.
94. Gressens P, Paindaveine B, Hill JM, Evrard P, Brenneman DE: Vasoactive intestinal peptide shortens both G1 and S phases of neural cell cycle in whole postimplantation cultured mouse embryos. Eur J Neurosci 1994; 10:1734-1742.
95. Tyrrell S, Landis SC: The appearance of NPY and VIP in sympathetic neuroblasts and subsequent alterations in their expression. J Neurosci 1994; 14:4529-4547.
96. Lim MA, Stack CM, Cuasay K, Stone MM, McFarlane HG, Waschek JA, Hill JM: Regardless of genotype, offspring of VIP-deficient female mice exhibit developmental delays and deficits in social behavior. Int J Dev Neurosci 2008; 26:423-434.
97. Graf AH, Hütter W, Hacker GW, Steiner H, Anderson V, Staudach A, Dietze O: Localization and distribution of vasoactive neuropeptides in the human placenta. Placenta 1996; 17:413-421.
98. Marzioni D, Fiore G, Giordano A, Nabissi M, Florio P, Verdenelli F, Petraglia F, Castellucci M: Placental expression of substance P and vasoactive intestinal peptide: evidence for a local effect on hormone release. J Clin Endocrinol Metab 2005; 90:2378-2383.
99. Deutsch PJ, Sun Y, Kroog GS: Vasoactive intestinal peptide increases intracellular cAMP and gonadotropin-alpha gene activity in JEG-3 syncytial trophoblasts. Constraints posed by desensitization. J Biol Chem 1990; 265:10274-10281.
100. Ottesen B, Ulrichsen H, Fahrenkrug J, Larsen JJ, Wagner G, Schierup L, Søndergaard F: Vasoactive intestinal polypeptide and the female genital tract: relationship to reproductive phase and delivery. Am J Obstet Gynecol 1982; 143:414-420.
101. Roca V, Calafat M, Larocca L, Ramhorst R, Farina M, Franchi AM, Pérez Leiros C: Potential immunomodulatory role of VIP in the implantation sites of prediabetic nonobese diabetic mice. Reproduction 2009; 138:733-742.
102. Larocca L, Hauk V, Calafat M, Roca V, Fraccaroli L, Franchi A, Ramhorst R, Pérez Leiros C: Modulation of macrophage inflammatory profile in pregnant nonobese diabetic (NOD) mice. Mol Cell Endocrinol 2011; 333:112-118.
103. Fraccaroli L, Alfieri J, Larocca L, Calafat M, Roca V, Lombardi E, Ramhorst R, Pérez Leirós C: VIP modulates the pro-inflammatory maternal response, inducing tolerance to trophoblast cells. Br J Pharmacol 2009; 156:116-126.
104. Fraccaroli L, Grasso E, Zeitler E, Lombardi E, Gogorza S, Etchepareborda JJ, Nagle C, Cortelezzi M, Pérez Leirós C, Ramhorst R: Modulation of maternal LIF producers T cells by trophoblast and paternal antigens. Am J Reprod Immunol 2011; 65:133-145.
105. Ilarregui JM, Croci DO, Bianco GA, Toscano MA, Salatino M, Vermeulen ME, Geffner JR, Rabinovich GA: Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 2009; 10:981-991.
106. Ramhorst RE, Giribaldi L, Fraccaroli L, Toscano MA, Stupirski JC, Romero MD, Durand ES, Rubinstein N, Blaschitz A, Sedlmayr P, Genti-Raimondi S, Fainboim L, Rabinovich GA: Galectin-1 confers immune privilege to human trophoblast: implications in recurrent fetal loss. Glycobiology 2012; 22:1374-1386.
107. Blois SM, Ilarregui JM, Tometten M, Garcia M, Orsal AS, Cordo-Russo R, Toscano MA, Bianco GB, Kobelt P, Handjiski B, Tirado I, Markert UR, Klapp BF, Poirier F, Szekeres-Bartho J, Rabinovich GA, Arck PC: A pivotal role for galectin-1 in fetomaternal tolerance. Nat Med 2007; 13:1450-1457.
108. Rabinovich GA, Croci DO: Regulatory circuits mediated by lectin-glycan interactions in autoimmunity and cancer. Immunity 2012; 36:322-335.
109. Than NG, Romero R, Kim CJ, McGowen MR, Papp Z, Wildman DE: Galectins: guardians of eutherian pregnancy at the maternal-fetal interface. Trends Endocrinol Metab 2012; 23:23-31.
110. Than NG, Erez O, Wildman DE, Tarca AL, Edwin SS, Abbas A, Hotra J, Kusanovic JP, Gotsch F, Hassan SS, Espinoza J, Papp Z, Romero R: Severe preeclampsia is characterized by increased placental expression of galectin-1. J Matern Fetal Neonatal Med 2008; 21:429-442.